Business
Parsortix potential in metastatic breast cancer
Parsortix potential in metastatic breast cancer.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 4111V Angle PLC 18 April 2016 \n\n\n\n\n\nFor immediate release\n\n\n 18 April 2016\n\n\n\n\n \nANGLE plc (\"the Company\")\n \nUSC PATIENT DATA DEMONSTRATES POTENTIAL OF PARSORTIX FOR METASTATIC BREAST CANCER LIQUID BIOPSY CLINICAL APPLICATION\n \nFirst head to head comparison of the results of the invasive metastatic biopsy with the results of a Parsortix liquid biopsy\n \nSuccess shows potential for a simple blood test to direct treatment for metastatic breast cancer \n \nANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company, is delighted to announce that the results of the University of Southern California (USC) Norris Comprehensive Cancer Center's ongoing work with ANGLE's Parsortix system have demonstrated the potential for the use of Parsortix as a liquid biopsy for metastatic breast cancer. \n \nUSC head to head patient data will be presented today at AACR 2016 (the American Association for Cancer Research Annual Meeting 2016), which demonstrates a statistically significant correlation in metastatic breast cancer between analysis of CTCs (circulating tumor cells) harvested from a simple blood test using Parsortix with similar analysis of tissue obtained from invasive biopsy of a secondary cancer site. The Directors believe that the data demonstrates the potential for the Parsortix liquid biopsy (simple blood test) to replace the invasive biopsy. \n \nMetastasis is responsible for the vast majority of breast cancer related deaths. Initial treatment recommendations for breast cancer are based on primary tumor biology from the initial solid biopsy at patient presentation. However, the recently updated ASCO (American Society of Clinical Oncology) guidelines call for biopsy of a metastatic site to guide the decision making for treatment as it is known that cancers change their status as disease progresses. Access to the secondary cancer site to obtain this tissue biopsy is challenging and requires the patient to undergo an invasive procedure, which causes trauma and delays treatment until they have recovered from the procedure. Furthermore the surgical intervention takes time to arrange, is expensive and diverts resources from care for the patient. \n \nA liquid biopsy to obtain cancer cells for analysis from a simple blood ...